期刊
CANCER LETTERS
卷 524, 期 -, 页码 91-102出版社
ELSEVIER IRELAND LTD
DOI: 10.1016/j.canlet.2021.10.013
关键词
Liquid biopsy; Biomarkers; Lung cancer; Early detection; Clinical management
类别
This article discusses the importance of liquid biopsies in the discovery of lung cancer biomarkers, introduces emerging blood-based minimally invasive biomarkers, and discusses their advantages and limitations. It also summarizes the progress of identified biomarkers for clinical management of lung cancer, and proposes a potential strategy for early detection of lung cancer using a combination of LDCT scans and biomarkers.
Currently, early detection of lung cancer relies on the characterisation of images generated from computed tomography (CT). However, lung tissue biopsy, a highly invasive surgical procedure, is required to confirm CTderived diagnostic results with very high false-positive rates. Hence, a non-invasive or minimally invasive biomarkers is essential to complement the existing low-dose CT (LDCT) for early detection, improve responses to a certain treatment, predict cancer recurrence, and to evaluate prognosis. In the past decade, liquid biopsies (e.g., blood) have been demonstrated to be highly effective for lung cancer biomarker discovery. In this review, the roles of emerging liquid biopsy-derived biomarkers such as circulating nucleic acids, circulating tumour cells (CTCs), long non-coding RNA (lncRNA), and microRNA (miRNA), as well as exosomes, have been highlighted. The advantages and limitations of these blood-based minimally invasive biomarkers have been discussed. Furthermore, the current progress of the identified biomarkers for clinical management of lung cancer has been summarised. Finally, a potential strategy for the early detection of lung cancer, using a combination of LDCT scans and well-validated biomarkers, has been discussed.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据